ATE93138T1 - Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. - Google Patents
Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.Info
- Publication number
- ATE93138T1 ATE93138T1 AT91904163T AT91904163T ATE93138T1 AT E93138 T1 ATE93138 T1 AT E93138T1 AT 91904163 T AT91904163 T AT 91904163T AT 91904163 T AT91904163 T AT 91904163T AT E93138 T1 ATE93138 T1 AT E93138T1
- Authority
- AT
- Austria
- Prior art keywords
- insulin sensitizing
- treat hypertension
- sensitizing agents
- insulin
- hypertension
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 230000001235 sensitizing effect Effects 0.000 title abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 abstract 1
- 229950009226 ciglitazone Drugs 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47809090A | 1990-02-09 | 1990-02-09 | |
| EP91904163A EP0514452B2 (de) | 1990-02-09 | 1991-01-23 | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie |
| PCT/US1991/000348 WO1991012003A1 (en) | 1990-02-09 | 1991-01-23 | Use of insulin sensitizing agents to treat hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE93138T1 true ATE93138T1 (de) | 1993-09-15 |
Family
ID=23898474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91904163T ATE93138T1 (de) | 1990-02-09 | 1991-01-23 | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0514452B2 (de) |
| JP (1) | JP3544659B2 (de) |
| KR (1) | KR0170416B1 (de) |
| AT (1) | ATE93138T1 (de) |
| AU (1) | AU651571B2 (de) |
| CA (1) | CA2071629C (de) |
| DE (1) | DE69100282T3 (de) |
| DK (1) | DK0514452T4 (de) |
| ES (1) | ES2059121T5 (de) |
| GR (1) | GR3034508T3 (de) |
| HK (1) | HK153996A (de) |
| WO (1) | WO1991012003A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175179A (en) * | 1991-09-25 | 1992-12-29 | Pfizer Inc. | Method for treating hypertension |
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| US5874454A (en) * | 1993-09-15 | 1999-02-23 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| US5925656A (en) * | 1995-04-10 | 1999-07-20 | Dr. Reddy's Research Foundation | Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| SK283348B6 (sk) * | 1996-04-05 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II |
| AU2381397A (en) * | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5919782A (en) * | 1996-05-06 | 1999-07-06 | Dr. Reddy's Research Foundation | Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| US5801173A (en) * | 1996-05-06 | 1998-09-01 | Dr. Reddy's Research Foundation | Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| ZA973848B (en) * | 1996-05-06 | 1997-12-02 | Reddy Research Foundation | Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them. |
| US5889025A (en) * | 1996-05-06 | 1999-03-30 | Reddy's Research Foundation | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| CA2257284C (en) * | 1996-05-31 | 2005-10-04 | Sankyo Company Limited | Remedy for autoimmune diseases |
| KR20000016074A (ko) * | 1996-05-31 | 2000-03-25 | 가와무라 요시부미 | 자기면역질환 치료제 |
| USRE39266E1 (en) * | 1996-07-01 | 2006-09-05 | Dr. Reddy's Laboratories, Limited | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| CA2258949C (en) | 1996-07-01 | 2008-05-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US6114526A (en) | 1996-07-01 | 2000-09-05 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US6372750B2 (en) | 1996-07-01 | 2002-04-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases |
| US6313113B1 (en) | 1997-04-15 | 2001-11-06 | Reddy-Cheminor, Inc. | Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| US6011031A (en) * | 1997-05-30 | 2000-01-04 | Dr. Reddy's Research Foundation | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them |
| AU9762798A (en) * | 1997-11-12 | 1999-05-31 | Kyoto Pharmaceutical Industries, Ltd. | Novel thiazolidine compounds and medicinal utilization thereof |
| WO2000027434A1 (en) * | 1998-11-11 | 2000-05-18 | Smithkline Beecham P.L.C. | Combinations comprising a beta-agonist and a further antidiabetic agent |
| PE20010580A1 (es) * | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
| EP2638898A1 (de) | 2012-03-16 | 2013-09-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen |
| EP3025707A1 (de) | 2014-11-27 | 2016-06-01 | Arven Ilac Sanayi Ve Ticaret A.S. | Mehrschichtige tablette mit metformin und pioglitazon |
| TR201620309A2 (tr) | 2016-12-30 | 2018-07-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542927A (en) * | 1965-08-10 | 1970-11-24 | Pfizer | Reduction of blood sugar levels with aminomethylindoles |
| DE2965655D1 (en) * | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| JPS5522636A (en) † | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| EP0052963B1 (de) * | 1980-11-20 | 1985-02-20 | Beecham Group Plc | Sekundäre Amine |
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| EP0142102B1 (de) † | 1983-11-04 | 1987-09-23 | Beecham Group Plc | Tertiäre Amine |
| US4602044A (en) † | 1983-12-19 | 1986-07-22 | Eli Lilly And Company | β-phenethanolamine antiobesity agents |
| DE3419935A1 (de) * | 1984-05-28 | 1985-11-28 | Merck Patent Gmbh, 6100 Darmstadt | Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks |
| AR240698A1 (es) † | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| GB8607312D0 (en) † | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
| FR2611500B1 (fr) * | 1987-03-06 | 1990-05-04 | Lipha | Emploi de derives du biguanide dans la preparation de medicaments |
| IE940525L (en) * | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
| GB8820389D0 (en) * | 1988-08-26 | 1988-09-28 | Beecham Group Plc | Novel compounds |
| US5143930A (en) * | 1990-02-07 | 1992-09-01 | Sankyo Company, Limited | Thiazolidine derivatives with anti-diabetic activity, their preparation and their use |
-
1991
- 1991-01-23 ES ES91904163T patent/ES2059121T5/es not_active Expired - Lifetime
- 1991-01-23 CA CA002071629A patent/CA2071629C/en not_active Expired - Fee Related
- 1991-01-23 DK DK91904163T patent/DK0514452T4/da active
- 1991-01-23 AT AT91904163T patent/ATE93138T1/de not_active IP Right Cessation
- 1991-01-23 AU AU72416/91A patent/AU651571B2/en not_active Ceased
- 1991-01-23 DE DE69100282T patent/DE69100282T3/de not_active Expired - Fee Related
- 1991-01-23 WO PCT/US1991/000348 patent/WO1991012003A1/en not_active Ceased
- 1991-01-23 JP JP50440791A patent/JP3544659B2/ja not_active Expired - Fee Related
- 1991-01-23 KR KR1019920701906A patent/KR0170416B1/ko not_active Expired - Fee Related
- 1991-01-23 EP EP91904163A patent/EP0514452B2/de not_active Expired - Lifetime
-
1996
- 1996-08-08 HK HK153996A patent/HK153996A/en not_active IP Right Cessation
-
2000
- 2000-09-28 GR GR20000402198T patent/GR3034508T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2071629A1 (en) | 1991-08-10 |
| HK153996A (en) | 1996-08-16 |
| EP0514452A1 (de) | 1992-11-25 |
| KR0170416B1 (ko) | 1999-02-18 |
| ES2059121T5 (es) | 2000-12-01 |
| GR3034508T3 (en) | 2000-12-29 |
| DE69100282D1 (de) | 1993-09-23 |
| JP3544659B2 (ja) | 2004-07-21 |
| ES2059121T3 (es) | 1994-11-01 |
| DK0514452T4 (da) | 2000-09-18 |
| DE69100282T3 (de) | 2001-01-11 |
| DE69100282T2 (de) | 1994-01-05 |
| DK0514452T3 (da) | 1993-11-29 |
| JPH05506430A (ja) | 1993-09-22 |
| CA2071629C (en) | 1997-12-30 |
| WO1991012003A1 (en) | 1991-08-22 |
| AU7241691A (en) | 1991-09-03 |
| AU651571B2 (en) | 1994-07-28 |
| EP0514452B1 (de) | 1993-08-18 |
| EP0514452B2 (de) | 2000-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69424537D1 (de) | Therapeutischer wirkstoff zur behandlung von melanomen | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE69116380D1 (de) | Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit | |
| ATE110958T1 (de) | Verwendung von sertralin zur behandlung verfrühter ejakulation. | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| DE69617729D1 (de) | Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom | |
| DE59107536D1 (de) | Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| FI951024A0 (fi) | Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät | |
| ATE157010T1 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
| DE69124382D1 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis | |
| DE68906028D1 (de) | Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |